Literature DB >> 17503126

Diagnostics of cognitive dysfunctions in multiple sclerosis.

Claudia Engel1, Brigitte Greim, Uwe K Zettl.   

Abstract

Cognitive dysfunctions are frequent symptoms in multiple sclerosis (MS). Up to 65% of MS patients suffer from cognitive dysfunctions. Especially memory, attention and executive functions are impaired. These problems strongly affect the patients' ability to work and their quality of life (QoL). A differentiating diagnostic effort is necessary to control fatigue and depression. Screening tools alone can not provide a detailed description of all cognitive domains. Therefore, an elaborated neuropsychological diagnostics is necessary. This report provides a description of cognitive functions and its diagnostic opportunities, especially in MS patients. After displaying aspects of differential diagnostics, a recommendation for a diagnostic work schedule is given.

Entities:  

Mesh:

Year:  2007        PMID: 17503126     DOI: 10.1007/s00415-007-2009-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  Fatigue and declines in cognitive functioning in multiple sclerosis.

Authors:  L B Krupp; L E Elkins
Journal:  Neurology       Date:  2000-10-10       Impact factor: 9.910

Review 2.  [Cognitive dysfunctions in multiple sclerosis patients].

Authors:  C Engel; B Greim; U K Zettl
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

3.  Paced auditory serial-addition task: a measure of recovery from concussion.

Authors:  D M Gronwall
Journal:  Percept Mot Skills       Date:  1977-04

4.  The relation between objective and subjective impairment in cognitive function among multiple sclerosis patients--the role of depression.

Authors:  Y Maor; L Olmer; B Mozes
Journal:  Mult Scler       Date:  2001-04       Impact factor: 6.312

Review 5.  Assessment of cognitive dysfunction in multiple sclerosis.

Authors:  Eric Sartori; Gilles Edan
Journal:  J Neurol Sci       Date:  2006-05-05       Impact factor: 3.181

Review 6.  Minimal neuropsychological assessment of MS patients: a consensus approach.

Authors:  Ralph H B Benedict; Jill S Fischer; Cate J Archibald; Peter A Arnett; William W Beatty; Julie Bobholz; Gordon J Chelune; John D Fisk; Dawn W Langdon; Lauren Caruso; Fred Foley; Nicholas G LaRocca; Lindsey Vowels; Amy Weinstein; John DeLuca; Stephen M Rao; Frederick Munschauer
Journal:  Clin Neuropsychol       Date:  2002-08       Impact factor: 3.535

Review 7.  Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.

Authors:  Bridget Bagert; Patricia Camplair; Dennis Bourdette
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

8.  Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI).

Authors:  W W Beatty; R H Paul; S L Wilbanks; K A Hames; C R Blanco; D E Goodkin
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

9.  The interaction between depressive affective disorder and neuropsychological test performance in multiple sclerosis patients.

Authors:  R B Schiffer; E D Caine
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1991       Impact factor: 2.198

Review 10.  Treatment optimization in multiple sclerosis: report of an international consensus meeting.

Authors: 
Journal:  Eur J Neurol       Date:  2004-01       Impact factor: 6.089

View more
  9 in total

1.  Structural correlates for fatigue in early relapsing remitting multiple sclerosis.

Authors:  Janine Wilting; Hans O Rolfsnes; Hilga Zimmermann; Marion Behrens; Vinzenz Fleischer; Frauke Zipp; Adriane Gröger
Journal:  Eur Radiol       Date:  2015-05-31       Impact factor: 5.315

Review 2.  Cognitive impairment in multiple sclerosis.

Authors:  Alexander Winkelmann; Claudia Engel; Annett Apel; Uwe K Zettl
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

3.  Cognitive dysfunction in multiple sclerosis.

Authors:  Joana Guimarães; Maria José Sá
Journal:  Front Neurol       Date:  2012-05-24       Impact factor: 4.003

4.  The effect of exercise therapy on cognitive functions in multiple sclerosis patients: A pilot study.

Authors:  Bahram Sangelaji; Fatemeh Estebsari; Seyed Massood Nabavi; Ensiyeh Jamshidi; Damineh Morsali; Maryam Dastoorpoor
Journal:  Med J Islam Repub Iran       Date:  2015-04-22

5.  Tissue transglutaminase in marmoset experimental multiple sclerosis: discrepancy between white and grey matter.

Authors:  Nathaly Espitia Pinzon; Esther Stroo; Bert A 't Hart; John G J M Bol; Benjamin Drukarch; Jan Bauer; Anne-Marie van Dam
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

6.  Cognitive and Language Deficits in Multiple Sclerosis: Comparison of Relapsing Remitting and Secondary Progressive Subtypes.

Authors:  Katerina Ntoskou; Lambros Messinis; Grigorios Nasios; Maria Martzoukou; Giorgos Makris; Elias Panagiotopoulos; Panagiotis Papathanasopoulos
Journal:  Open Neurol J       Date:  2018-03-12

7.  Efficacy of a short cognitive training program in patients with multiple sclerosis.

Authors:  María Yaiza Pérez-Martín; Montserrat González-Platas; Pablo Eguía-Del Río; Cristina Croissier-Elías; Alejandro Jiménez Sosa
Journal:  Neuropsychiatr Dis Treat       Date:  2017-02-03       Impact factor: 2.570

8.  Astrocyte-derived tissue Transglutaminase affects fibronectin deposition, but not aggregation, during cuprizone-induced demyelination.

Authors:  Nathaly Espitia Pinzon; Berta Sanz-Morello; John J P Brevé; John G J M Bol; Benjamin Drukarch; Jan Bauer; Wia Baron; Anne-Marie van Dam
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

9.  Efficacy of a Computer-Assisted Cognitive Rehabilitation Intervention in Relapsing-Remitting Multiple Sclerosis Patients: A Multicenter Randomized Controlled Trial.

Authors:  Lambros Messinis; Grigorios Nasios; Mary H Kosmidis; Petros Zampakis; Sonia Malefaki; Katerina Ntoskou; Anastasia Nousia; Christos Bakirtzis; Nikolaos Grigoriadis; Philippos Gourzis; Panagiotis Papathanasopoulos
Journal:  Behav Neurol       Date:  2017-12-31       Impact factor: 3.342

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.